In the medical literature, there are case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C
Cryoglobulinemia is a disorder caused by the hepatitis C virus. The symptoms and health problems of cryoglobulinemia lead to mild to moderate to severe disease and for some people, it can be life-threatening. Treating cryoglobulinemia with direct-acting antiviral medications has been shown to reduce the symptoms of the disease and for some, it can lead to a remission and cure of cryoglobulinemia.
This objective of this clinical trial is to treat and cure hepatitis C genotype 1 and measure the effect of curing or reducing the complications of hepatitis C-related cryoglobulinemia.
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
To view the entire clinical trial information, click here